Introduction
Salivary gland tumors, occupying 22 .7% of all oral and maxillofacial tumors, are relatively common in oral and maxillofacial tumors (1) and contain various histologic types (2) . Epithelium-derived salivary gland tumors make up the majority, while tumors derived from other tissues (such as mesenchymal tissue) are rare. The parotid gland is the largest gland in the salivary gland, a site susceptible to developing tumors or tumor-like lesions. The incidence of parotid gland tumors accounts for about 80% of all salivary gland tumors. The majority of parotid gland tumors are benign (about 75%); malignant tumors only make up about 25% of the total. The pathology of parotid gland tumors is complex, while their clinical manifestations, treatment, and prognosis are quite different (3) . Malignant parotid gland tumors mostly derive from epithelial cells of parotid glands or gland ducts. Mucoepidermoid tumors, malignant mixed tumors, adenoid cystic carcinoma, and adenocarcinoma are common types, accounting for 80%-90% of malignant parotid gland tumors. Modern molecular biological studies have demonstrated that the activation of oncogenes and the loss of function of tumorsuppressor genes play a crucial role in carcinogenesis. Currently, there is no molecular biomarker for malignant parotid gland tumors in clinical treatment. Therefore, it is important to study the pathogenesis and the early diagnosis of malignant parotid gland tumors.
P53, P63, and P73 are widely studied in tumorigenesis and highly expressed in various types of tumors. So far, P53 is the tumor-suppressor gene that is the most closely related with human tumors (4) . It plays key roles in cell cycle regulation, cell growth inhibition, and apoptosis in tumor cells. More than 50% of human tumors contain a P53 gene mutation. P63, a homolog of P53, is a transcription factor. P63 plays an important role in the development, differentiation, and morphogenesis of epithelial tissue. Studies found that the P73 protein increased in many types of tumors including lung cancer (5), colon cancer (6), ovarian cancer (7), endometrial cancer (8) , and breast cancer (9) , while it decreased in pediatric acute lymphocytic leukemia (10) . However, studies of these 3 factors in malignant parotid gland tumors are rarely reported. Our present study investigated P53, P63, and P73 expression in malignant parotid gland tumors using immunohistochemistry (IHC), and the relationship of their clinical characteristics, to provide information for diagnosis and individualized treatment for malignant parotid gland tumors. 
Materials and methods

Specimens
Immunohistochemistry
Expression of P53, P63, and P73 protein was detected using an immunohistochemical S-P kit (MaiXin Bio, China) according to the manufacturer's instructions. Specific antibodies to P53 (MaiXin Bio), P63 (MaiXin Bio), and P73 (Bioss, China) were used as the first antibodies. The P53 antibody recognized the aa37-45 at the N-terminal of the whole P53. P63 and P73 antibodies also recognized the N-terminal of the P63 and P73 proteins. PBS buffer, instead of the first antibodies, was used as the negative control. Hematoxylin was used for counterstaining (in blue). Each section was observed in 10 random fields under 100× magnification. The overall IHC score (0, 1, 1.5-2, 2.5-3) was calculated by adding intensity (0, no staining; 1, light yellow; 2, orange-yellow; 3 brown) and proportion of positively stained cells (0, <10%; 1, 10%-50%; 2, 50%-75%; 3, >75%), and then dividing the sum by 2. Expression of P53, P63, and P73 was categorized as negative (IHC score = 0) or positive (IHC score > 0) for future analysis. Each slide was reviewed by 2 pathologists independently.
Statistical analysis
Statistical analysis was performed using SPSS 13.0. The chi-square test was used to compare P53, P63, and P73 protein expression and the clinical characteristics of malignant parotid gland tumors. Statistical significance was established at P < 0.05.
Results
We detected P53, P63, and P73 protein expression in 40 malignant parotid gland tumors and paired adjacent nonneoplastic tissues using IHC. Expressions of the 3 proteins in each subtype of tumors are listed in Table 1 . We found that 28 (70%), 26 (65%), and 27 (67.5%) out of 40 tumor specimens expressed the P53, P63, and P73 proteins, respectively. On the contrary, 2 (5%), 2 (5%), and 0 (0%) adjacent nonneoplastic tissues expressed P53, P63, and P73 proteins (P = 0.030, 0.001, and 0.001, respectively; Table 2 ). Positive staining of the P53 protein was mainly located in the nuclei in adenoid cystic carcinoma, mucoepidermoid tumors, and adenocarcinoma ( Figure 1 , indicated by arrows). We found that the P63 protein also showed positive staining in the nuclei of adenoid cystic carcinoma and mucoepidermoid tumors, instead of in adenocarcinoma ( Figure 2 , indicated by arrows). P63 expression was observed in the nuclei of myoepithelium in the glands of nonneoplastic tissue of adenocarcinoma ( Figure   2 , indicated by arrow). The P73 protein was mainly located in the nuclei, with a little in the cytoplasm, and was diffusely stained in adenoid cystic carcinoma, mucoepidermoid tumors, and adenocarcinoma ( Figure  3 , indicated by arrows). 
Nonneoplastic tissue
The expression of P53, P63, and P73 protein was not associated with age or sex of patients or lymph node metastasis of malignant parotid gland tumors (P > 0.05, Table 3 ). Expression of the P53 and P73 protein, but not the P63 protein, was correlated to degree of malignancy (P = 0.026 and 0.018, respectively; Table 3 ). In total, 2, 2, 1, and 4 high malignant tumors were observed to have P53/ P63, P53/P73, and P63/P73 double-positive staining and P53/P63/P73 triple-positive staining, respectively (Table   4 ). Lymph node metastasis was found in P53/P73 and P63/P73 double-positive and P53/P63/P73 triple-positive samples (Table 4 ). There was no significant difference among the expressions of P53, P73, and P63 proteins in malignant parotid gland tumors (P > 0.05, Table 5 ). In the follow-up, ranging from 5 months to 3 years, only 1 patient died of colon cancer, which indicates that expression of the P53, P63, and P73 proteins may not be involved in the prognosis of malignant parotid gland tumors. 
Discussion
High expression of P53 protein represents a high degree of malignancy and poor prognosis in oral tumors (11) . Expression of the P53 protein increased in malignant salivary gland tumors (12) (13) (14) and was correlated with poor differentiation, high degrees of malignancy, and poor prognosis (15) . The mutation rate of the P53 gene varies in oral and maxillofacial tumors (12) . Studies suggest that the conformation change of mutant P53 facilitates malignant cells escaping from regulation and immortalization. Ki-67 is a nuclear protein that indicates cellular proliferation, and it is expressed in most proliferative cells. It is reported that the expression of Ki-67 and P53 coexists in malignant salivary gland tumors (16) , indicating that dysregulation of proliferative genes and loss of function of tumorsuppressor genes interacts in concert in the development of salivary gland tumors. We detected P53 protein expression in malignant parotid gland tumors and adjacent nonneoplastic tissues using IHC and found that high expressions of the P53 protein in tumor tissues compared to adjacent nonneoplastic tissues correlated with degree of malignancy. P53 may be an important biomarker for degree of malignancy and prognosis of malignant parotid gland tumors. Different splicing and promoters produce 6 isoforms of P63, including ΔN and TAp63. ΔNP63 is essential for the development, differentiation, and homeostasis of the oral squamous epithelium (17) . In oral tumors, ΔNP63 binds to the DNA through its DNA binding domain or directly interacts with P53 or TAP63, which makes ΔNP63 inhibit cell apoptosis and perform the function of an oncogene in the occurrence of oral tumors (18, 19) . P63 also plays an important role in oral squamous cell carcinoma (20, 21) . P63 was involved in the physiopathology of the oral mucosa (20) . Low P63 gene mutation rates but increased expression of ΔNP63α was found in oral squamous cell carcinoma (21) .
High P63 expression was reported in salivary gland tumors (22, 23) . Bilal et al. (24) found strong expressions of P63 in myoepithelial cells, while weak expressions were seen in the cellular lumen in mucoepidermoid carcinoma. P63 was expressed in the basal cells of emunctories in normal salivary gland tissue, while in salivary gland tumors P63 was expressed in myoepithelial cells, and especially in the myoepithelial cells of malignant salivary gland tumors (25) . The different expressions of P63 in normal and malignant salivary gland tissues may be applied to the diagnosis of salivary gland tumors. Our results found that expression of P63 protein in malignant parotid gland tumors was higher than that in adjacent nonneoplastic tissues, indicating that the overexpression of P63 protein was closely related to the development of malignant parotid gland tumors.
Loss of heterozygosity (LOH) and methylation of P73 was associated with tumorigenesis. Araki et al. (26) found LOH in 31 of 41 (73%) oral cancers, high methylation of the CpG island in the P73 gene promoter, and decreased expression of mRNA. In tumor tissue with P73 gene methylation, no or low transcriptional levels of P73 mRNA might lead to tumorigenesis. Expression of P73 increased in oral squamous cell carcinoma compared to that in normal oral mucosa (27, 28) . Elevated expression of the P73 protein was found in oral precancerous lesions and squamous cell carcinoma (29, 30) , indicating that P73 expression was involved in the carcinogenesis from normal oral mucosa to precancerous lesions and squamous cell carcinoma. P73 expression was positively correlated to lymph node metastasis in oral squamous cell carcinoma (28) (29) (30) , suggesting that tumors with high P73 expression were more invasive than those with low or no expression of P73.
Although P73 has been widely studied in many types of tumors, the P73 gene's function has not been clarified (29) ; in particular, P73 expression in malignant parotid gland tumors and its correlation with degree of malignancy have Studies showed that P73 arrested cell growth and induced apoptosis by activating the specific target genes of P53 and that different splicing isoforms of P53 and P73 activated distinct target genes. Therefore, P53 and P73 signaling pathways were partially overlapped (33) . Positive correlation between P53 protein and P73 protein was found in oral squamous carcinoma (28) , gastric cancer (34) , and osteosarcoma (35) . Recent studies suggested that P73 might not be a tumor suppressor gene, but rather an analog of P53, which can simulate P53's function and therefore cause the P53 gene to lose function, subsequently leading to cellular malignancy (36, 37) . Our results showed that expression of P53 and P73 proteins was not significantly different in malignant parotid gland carcinoma (P > 0.05), which was consistent with other studies (38) . Our results suggested that the function of P53 and P73 proteins might be independent from the development of malignant parotid gland tumors. At the same time, our results showed that there was no significant difference between the expression of P53 and P63 proteins and that of P73 and P63 proteins in malignant parotid gland carcinoma (P > 0.05).
We found a high expression of P53, P63, and P73 proteins in malignant tumors of the parotid gland, suggesting that P53, P63, and P73 proteins may play a role in the development of malignant parotid gland tumors. After further study of the functions and regulation mechanisms of P53, P63, and P73 genes, new insight will be revealed on the carcinogenesis of oral tumors and early molecular intervention will become possible.
